Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Head and Neck Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 21 articles:
HTML format



Single Articles


    November 2022
  1. LUMISH MA, Maron SB, Paroder V, Chou JF, et al
    Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: a pilot study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264470. doi: 10.2967/jnumed.122.264470.
    PubMed     Abstract available


  2. ZHOU Q, van den Berg NS, Kang W, Pei J, et al
    Factors for Differential Outcome Across Cancers in Clinical Molecule-Targeted Fluorescence Imaging.
    J Nucl Med. 2022;63:1693-1700.
    PubMed     Abstract available


    October 2022
  3. HU X, Zhou T, Ren J, Duan J, et al
    Response prediction using (18)F-FAPI-04 PET/CT in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy.
    J Nucl Med. 2022 Oct 13. pii: jnumed.122.264638. doi: 10.2967/jnumed.122.264638.
    PubMed     Abstract available


    August 2022
  4. KRISHNAN G, van den Berg NS, Nishio N, Kapoor S, et al
    Fluorescent Molecular Imaging Can Improve Intraoperative Sentinel Margin Detection in Oral Squamous Cell Carcinoma.
    J Nucl Med. 2022;63:1162-1168.
    PubMed     Abstract available


    June 2022
  5. ZHENG KH, Kroon J, Schoormans J, Gurney-Champion O, et al
    (89)Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.
    J Nucl Med. 2022 Jun 23. pii: jnumed.121.263330. doi: 10.2967/jnumed.121.263330.
    PubMed     Abstract available


  6. AVRAM AM, Giovanella L, Greenspan B, Lawson SA, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.
    J Nucl Med. 2022;63:15N-35N.
    PubMed    


    May 2022
  7. SUBRAMANIAM RM, Duan F, Romanoff J, Yu JQ, et al
    (18)F FDG PET/CT Staging of Head and Neck Cancer: Inter-observer agreement and accuracy - Results from multicenter ACRIN 6685 Clinical Trial.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263902. doi: 10.2967/jnumed.122.263902.
    PubMed     Abstract available


  8. VERHOEFF SR, van de Donk PP, Aarntzen EHJG, Oosting SF, et al
    (89)Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer.
    J Nucl Med. 2022 May 5. pii: jnumed.121.263470. doi: 10.2967/jnumed.121.263470.
    PubMed     Abstract available


    February 2022
  9. SIGNORE A, Campagna G, Marinaccio J, de Vitis M, et al
    Analysis of short term and stable DNA damage in patients with differentiated thyroid cancer treated with (131)I in hypothyroidism or with rhTSH for remnant ablation.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263442. doi: 10.2967/jnumed.121.263442.
    PubMed     Abstract available


    December 2021
  10. CREFF G, Jegoux F, Palard-Novello X, Depeursinge A, et al
    FDG-PET/CT-based prognostic survival model after surgery for head and neck cancer.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262891. doi: 10.2967/jnumed.121.262891.
    PubMed     Abstract available


  11. RISOER LM, Clausen MM, Ujmajuridze Z, Farhadi M, et al
    Prognostic value of Urokinase-type Plasminogen Activator Receptor (uPAR)-PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with (18)F-FDG-PET/CT: A single-center prospective study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262866. doi: 10.2967/jnumed.121.262866.
    PubMed     Abstract available


  12. PROMTEANGTRONG C, Siripongsatian D, Jantarato A, Kunawudhi A, et al
    Head-to-head comparison of (68)Ga-FAPI-46 and (18)F-FDG PET/CT for evaluation of head and neck squamous cell carcinoma: a single-center exploratory study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262831. doi: 10.2967/jnumed.121.262831.
    PubMed     Abstract available


    September 2021
  13. GU B, Xu X, Zhang J, Ou X, et al
    The Added Value of (68)Ga-FAPI-04 PET/CT in Patients with Head and Neck Cancer of Unknown Primary with (18)F-FDG Negative Findings.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262790. doi: 10.2967/jnumed.121.262790.
    PubMed     Abstract available


  14. VONK J, de Wit JG, Voskuil FJ, Tang YH, et al
    Epidermal growth factor receptor targeted fluorescence molecular imaging for postoperative lymph node assessment in patients with oral cancer.
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262530. doi: 10.2967/jnumed.121.262530.
    PubMed     Abstract available


    August 2021
  15. AVRAM AM, Zukotynski K, Nadel HR, Giovanella LM, et al
    MANAGEMENT OF DIFFERENTIATED THYROID CANCER: THE STANDARD OF CARE.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262402. doi: 10.2967/jnumed.121.262402.
    PubMed     Abstract available


    July 2021
  16. GIOVANELLA L, Avram A, Clerc J
    Molecular Imaging for Thyrotoxicosis and Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  17. BERNET VJ, Chindris AM
    Update on the Evaluation of Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  18. DE SOUZA FRANCA PD, Guru N, Kostolansky AR, Mauguen A, et al
    PARP1: A Potential Molecular Marker to Identify Cancer During Colposcopy Procedures.
    J Nucl Med. 2021;62:941-948.
    PubMed     Abstract available


    March 2021
  19. HOPE TA, Graces C, Calais J, Ehman E, et al
    Accuracy of (18)F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study.
    J Nucl Med. 2021 Mar 5. pii: jnumed.120.256735. doi: 10.2967/jnumed.120.256735.
    PubMed     Abstract available


    January 2021
  20. WHITMAN J, Allen IE, Bergsland EK, Suh IA, et al
    Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis.
    J Nucl Med. 2021 Jan 15. pii: jnumed.120.257303. doi: 10.2967/jnumed.120.257303.
    PubMed     Abstract available


    May 2020
  21. CHENG L, Sa R, Luo Q, Fu H, et al
    Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients Indicates Radioiodine Adjuvant Therapy: A Prospective Multicenter Study.
    J Nucl Med. 2020 May 1. pii: jnumed.120.243642. doi: 10.2967/jnumed.120.243642.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: